ライフサイエンスコーパス: neutrophil gelatinase-associated lipocalin

1 arkers (such as kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin).

2 OB-4 and keratin 20), and immune modulation (neutrophil-gelatinase-associated lipocalin).

3 L-6 expression and resulted in lower urinary neutrophil gelatinase-associated lipocalin.

4 in the serum biomarkers BUN, creatinine, and neutrophil gelatinase-associated lipocalin.

5 levels of a marker of neutrophil activation neutrophil gelatinase-associated lipocalin.

6 ry excretion of kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin.

7 acid inhibited induction of c-fos, junb, and neutrophil gelatinase-associated lipocalin.

8 s, apoptosis, urinary kidney damage markers, neutrophil gelatinase-associated lipocalin 1, and interl

9 group (P = 0.0004), and was noninferior for neutrophil gelatinase-associated lipocalin [14.7 mug/L (

10 Urine neutrophil gelatinase-associated lipocalin, a marker of

11 luble Tek/Tie2 receptor and in urinary MMP-9/neutrophil gelatinase-associated lipocalin activity afte

12 s no difference in concentrations of urinary neutrophil gelatinase-associated lipocalin after the 2 i

13 ant interaction between the concentration of neutrophil gelatinase-associated lipocalin, an establish

14 ression determined the prognostic utility of neutrophil gelatinase-associated lipocalin and creatinin

15 These include a plasma panel (neutrophil gelatinase-associated lipocalin and cystatin

16 retion associated with AKI severity, and for neutrophil gelatinase-associated lipocalin and cystatin

17 Neutrophil gelatinase-associated lipocalin and liver fat

18 ge, as indicated by higher values of urinary neutrophil gelatinase-associated lipocalin and microalbu

19 Serum neutrophil gelatinase-associated lipocalin and serum int

20 superior urinary output, and reduced urinary neutrophil gelatinase-associated lipocalin and tissue in

21 Urinary neutrophil gelatinase-associated lipocalin and urinary k

22 rmine the prognostic utility of both urinary neutrophil gelatinase-associated lipocalin and varying c

23 Others were plasma NGAL (neutrophil gelatinase-associated lipocalin) and NT-proBN

24 blood urea nitrogen, proteinuria and urinary neutrophil gelatinase-associated lipocalin) and serum cy

25 jury biomarkers kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin, and doses>/=

26 The role of serum cystatin C (Scyc), neutrophil gelatinase-associated lipocalin, and interleu

27 Biomarkers, neutrophil gelatinase-associated lipocalin, and kidney i

28 18), connective tissue growth factor (CTGF), neutrophil gelatinase-associated lipocalin, and kidney i

29 NET components (elastase, histones, neutrophil gelatinase-associated lipocalin, and proteina

30 nt levels of high-mobility group protein B1, neutrophil gelatinase-associated lipocalin, and S100B we

31 Additionally, levels of cell-free DNA, neutrophil gelatinase-associated lipocalin, and soluble

32 cular cell adhesion molecule, periostin, and neutrophil gelatinase-associated lipocalin; and a two-fo

33 rkers of kidney injury, BUN, creatinine, and neutrophil gelatinase-associated lipocalin as well as hi

34 Serum neutrophil gelatinase-associated lipocalin at day 3 was

35 r (95% confidence interval 1.5, 140) urinary neutrophil gelatinase-associated lipocalin at six hours

36 The upper quartile of urinary neutrophil gelatinase-associated lipocalin best predicte

37 Incubation of the progel B-TIMP-1-neutrophil gelatinase-associated lipocalin complex with

38 asma creatinine, glomerular filtration rate, neutrophil gelatinase-associated lipocalin concentration

39 osttransplant outcomes, or cell-free DNA and neutrophil gelatinase-associated lipocalin concentration

40 ure for serum creatinine, interleukin-6, and neutrophil gelatinase-associated lipocalin concentration

41 il gelatinase-associated lipocalin, or urine neutrophil gelatinase-associated lipocalin/creatinine ra

42 of known markers of renal injury, including neutrophil gelatinase-associated lipocalin, CXCL1, and C

43 ) kidney injury proteins (osteopontin [OPN], neutrophil gelatinase-associated lipocalin, cystatin C,

44 rs (chemokine [C-C motif] ligand 14 [CCL14], neutrophil gelatinase-associated lipocalin, dipeptidyl p

45 greater reduction in C-reactive protein and neutrophil gelatinase-associated lipocalin; fewer dialys

46 xpression of the MR and downstream molecules neutrophil gelatinase-associated lipocalin, galectin-3,

47 urinary levels of the iron acceptor proteins neutrophil gelatinase-associated lipocalin, hemopexin, a

48 serum levels of novel biomarkers, including neutrophil gelatinase-associated lipocalin, high-mobilit

49 Kidney injury biomarker levels (neutrophil gelatinase-associated lipocalin, IL-18, and k

50 sured the following five urinary biomarkers: neutrophil gelatinase-associated lipocalin, IL-18, kidne

51 al AKI, the highest tertiles of peak urinary neutrophil gelatinase-associated lipocalin, IL-18, KIM-1

52 f serum blood urea nitrogen, creatinine, and neutrophil gelatinase-associated lipocalin in post-ische

53 unction, reduced sC5b-9, and reduced urinary neutrophil gelatinase-associated lipocalin in the first

54 valuation of novel urinary biomarkers (e.g., neutrophil gelatinase-associated lipocalin) in this pati

55 lipocalin and cystatin C) and a urine panel (neutrophil gelatinase-associated lipocalin, interleukin

56 A biomarker panel of neutrophil gelatinase-associated lipocalin, interleukin-

57 IMP-1 in a ternary complex with progel B and neutrophil gelatinase-associated lipocalin is also susce

58 mporal change markers of renal injury (urine neutrophil gelatinase-associated lipocalin, kidney injur

59 6 hours after surgery) urine interleukin 18, neutrophil gelatinase-associated lipocalin, kidney injur

60 cohort study, 5 urinary biomarkers (urinary neutrophil gelatinase-associated lipocalin, kidney injur

61 donor urine injury biomarkers microalbumin, neutrophil gelatinase-associated lipocalin, kidney injur

62 , gamma-glutamyl transpeptidase, cystatin C, neutrophil gelatinase-associated lipocalin, kidney injur

63 put <0.5 mL/kg/h for >/=12 hours) and plasma neutrophil gelatinase-associated lipocalin level higher

64 In our adjusted models, enrollment neutrophil gelatinase-associated lipocalin level was ind

65 The discriminatory power of enrollment neutrophil gelatinase-associated lipocalin level was the

66 Serum neutrophil gelatinase-associated lipocalin levels are st

67 Creatinine levels in the plasma and urine, neutrophil gelatinase-associated lipocalin levels, Kidne

68 At baseline, urine-neutrophil-gelatinase-associated lipocalin levels were s

69 However, day 7 and 14 urine-neutrophil-gelatinase-associated lipocalin levels were s

70 kedly regulated the expression of NGAL/LCN2 (neutrophil gelatinase-associated lipocalin/lipocalin 2),

71 e GAM (neutrophil elastase, myeloperoxidase, neutrophil gelatinase-associated lipocalin, matrixmetall

72 Combining both DeltaSCr-initial and neutrophil gelatinase-associated lipocalin measured 3 ho

73 al perfusion and blood flow, whereas GFR and neutrophil gelatinase-associated lipocalin, monocyte che

74 n addition, we measured renal vein levels of neutrophil gelatinase-associated lipocalin, monocyte che

75 y hydroxyproline assay and quantification of neutrophil gelatinase-associated lipocalin mRNA.

76 Neutrophil gelatinase-associated lipocalin, myeloperoxid

77 (Acute Kidney Injury Neutrophil Gelatinase-Associated Lipocalin [N-GAL] Evalu

78 alidated renal tubular injury markers, NGAL (neutrophil gelatinase-associated lipocalin), NAG (N-acet

79 leucocyte activation/inflammation-Resistin, Neutrophil Gelatinase Associated Lipocalin (NGAL) and a

80 Human neutrophil gelatinase associated lipocalin (NGAL) was fo

81 Neutrophil gelatinase associated lipocalin (NGAL), a con

82 ns, the overall structure is most similar to neutrophil gelatinase associated lipocalin (NGAL), a pro

83 t AKI recognition using the novel biomarker, neutrophil gelatinase associated lipocalin (NGAL), combi

84 3, tumour necrosis factor-alpha (TNF-alpha), neutrophil gelatinase-associated lipocalin (NGAL) and me

85 p70, IL-13, tumor necrosis factor-a (TNF-a), neutrophil gelatinase-associated lipocalin (NGAL) and me

86 ed urine markers of kidney injury, including neutrophil gelatinase-associated lipocalin (NGAL) and po

87 e investigated whether cystatin C (CysC) and neutrophil gelatinase-associated lipocalin (NGAL) can pr

88 MMP-9/neutrophil gelatinase-associated lipocalin (NGAL) comple

89 helial cell-specific molecule-1 (ECM-1), and neutrophil gelatinase-associated lipocalin (NGAL) concen

90 label-free electrochemical immunosensor for neutrophil gelatinase-associated lipocalin (NGAL) detect

91 , the lipocalin-2 (Lcn2) gene, which encodes neutrophil gelatinase-associated lipocalin (NGAL) had th

92 Urinary neutrophil gelatinase-associated lipocalin (NGAL) has em

93 dy was to investigate the prognostic role of neutrophil gelatinase-associated lipocalin (NGAL) in a l

94 tility of kidney injury molecule (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL) in ear

95 amer-based sensor for the rapid detection of neutrophil gelatinase-associated lipocalin (NGAL) in uri

96 Neutrophil gelatinase-associated lipocalin (NGAL) is a 2

97 Urine neutrophil gelatinase-associated lipocalin (NGAL) is a b

98 Neutrophil gelatinase-associated lipocalin (NGAL) is a d

99 Previous research suggests that neutrophil gelatinase-associated lipocalin (NGAL) is a h

100 Neutrophil gelatinase-associated lipocalin (NGAL) is a n

101 Neutrophil gelatinase-associated lipocalin (NGAL) is a s

102 We tested the hypothesis that neutrophil gelatinase-associated lipocalin (NGAL) is an

103 Neutrophil gelatinase-associated lipocalin (NGAL) is an

104 rochemical immunosensor for the detection of neutrophil gelatinase-associated lipocalin (NGAL) is dev

105 Neutrophil gelatinase-associated lipocalin (NGAL) is exp

106 udy was to determine the association between neutrophil gelatinase-associated lipocalin (NGAL) levels

107 s higher (P = 0.031), and the level of urine neutrophil gelatinase-associated lipocalin (NGAL) was lo

108 Neutrophil gelatinase-associated lipocalin (NGAL) was re

109 metalloproteinase (MMP)-3, MMP-8, MMP-9, and neutrophil gelatinase-associated lipocalin (NGAL) were f

110 bronectin, interleukin-8 (IL-8), biotin, and neutrophil gelatinase-associated lipocalin (NGAL) were t

111 tly, the secreted protein 24p3 (lipocalin-2, neutrophil gelatinase-associated lipocalin (NGAL)), whic

112 ntrasted the results with those obtained for neutrophil gelatinase-associated lipocalin (NGAL), a com

113 We explored the expression of neutrophil gelatinase-associated lipocalin (NGAL), a mar

114 t HGF stimulates epithelial cells to express neutrophil gelatinase-associated lipocalin (Ngal), a mem

115 med to assess the prognostic value of plasma neutrophil gelatinase-associated lipocalin (NGAL), a nov

116 injury, podocyte damage, and elevated renal neutrophil gelatinase-associated lipocalin (NGAL), along

117 Neutrophil gelatinase-associated lipocalin (Ngal), also

118 ti-DNA antibodies induced high expression of neutrophil gelatinase-associated lipocalin (NGAL), an ir

119 (AAG), transferrin (TF), ceruloplasmin (CP), neutrophil gelatinase-associated lipocalin (NGAL), and m

120 ized genes was further characterized, namely neutrophil gelatinase-associated lipocalin (NGAL), becau

121 dney transplant patients to evaluate urinary neutrophil gelatinase-associated lipocalin (NGAL), IL-18

122 Median values for neutrophil gelatinase-associated lipocalin (NGAL), inter

123 ing of these novel AKI biomarkers, including neutrophil gelatinase-associated lipocalin (NGAL), kidne

124 ate the diagnostic and prognostic utility of Neutrophil gelatinase-associated lipocalin (NGAL), Kidne

125 This study measured levels of neutrophil gelatinase-associated lipocalin (NGAL), kidne

126 Urine neutrophil gelatinase-associated lipocalin (NGAL), kidne

127 ured urinary concentrations of microalbumin, neutrophil gelatinase-associated lipocalin (NGAL), kidne

128 s compared with urinary interleukin (IL)-18, neutrophil gelatinase-associated lipocalin (NGAL), kidne

129 Urinary neutrophil gelatinase-associated lipocalin (NGAL), monom

130 postoperative measures of urine IL-18, urine neutrophil gelatinase-associated lipocalin (NGAL), or pl

131 postoperative measures of urine IL-18, urine neutrophil gelatinase-associated lipocalin (NGAL), or pl

132 With 10% increase in standardized urine Neutrophil gelatinase-associated lipocalin (NGAL), serum

133 oparticle-based immunoassay for detection of neutrophil gelatinase-associated lipocalin (NGAL), which

134 ntibodies specific for human MMP-9 and human neutrophil gelatinase-associated lipocalin (NGAL).

135 reduced for neutrophil collagenase (NC) and neutrophil gelatinase-associated lipocalin (NGAL).

136 being a complex of gelatinase B (MMP-9) and neutrophil gelatinase-associated lipocalin (NGAL).

137 P7), kidney injury molecule-1 (KIM-1) and/or neutrophil gelatinase-associated lipocalin (NGAL).

138 duced expression of the kidney injury marker Neutrophil Gelatinase-Associated Lipocalin (NGAL).

139 y isolated from human neutrophils and termed neutrophil gelatinase-associated lipocalin (NGAL).

140 eatinine ratio (ACR), and urinary and plasma neutrophil gelatinase-associated lipocalin (NGAL); each

141 The neutrophil gelatinase-associated lipocalin (NGAL, also k

142 dentified as a neutrophil granule component, neutrophil gelatinase-associated lipocalin (NGAL; also c

143 injury (kidney injury molecule-1 [KIM-1] and neutrophil gelatinase-associated lipocalin [NGAL]) and o

144 Lipocalin 2 (Lcn2; 24p3; neutrophil gelatinase-associated lipocalin [NGAL]) is an

145 and in combination) of 4 urinary biomarkers (neutrophil gelatinase-associated lipocalin [NGAL], inter

146 damage (kidney injury molecule-1, KIM-1 and neutrophil gelatinase-associated lipocalin, NGAL), kidne

147 pe plasminogen activator receptor, suPAR and neutrophil gelatinase-associated lipocalin, NGAL.

148 siderocalin (SCN; also known as lipocalin 2, neutrophil gelatinase-associated lipocalin/NGAL, or 24p3

149 Primary outcome was noninferiority for urine neutrophil gelatinase-associated lipocalin on the day af

150 siderocalin (SCN; also known as lipocalin-2, neutrophil gelatinase-associated lipocalin, or 24p3) int

151 n groups regarding plasma creatinine, plasma neutrophil gelatinase-associated lipocalin, or urine neu

152 was to assess the diagnostic value of plasma neutrophil gelatinase-associated lipocalin (pNGAL) for t

153 We found that leptospiremia, plasma neutrophil gelatinase-associated lipocalin (pNGAL), and

154 rkers tested, the optimal 3-marker panel was neutrophil gelatinase-associated lipocalin, protein C, a

155 Urine neutrophil gelatinase-associated lipocalin remained inde

156 ll as pimelylcarnitine linked with levels of neutrophil gelatinase-associated lipocalin representing

157 d for assessments of blood urea nitrogen and neutrophil gelatinase-associated lipocalin, respectively

158 the mouse and human homologues 24p3/lcn2 and neutrophil gelatinase-associated lipocalin, show great f

159 eated participants with AKI had higher urine-neutrophil-gelatinase-associated lipocalin, suggesting t

160 redox-active iron, interleukin (IL)-18, and neutrophil gelatinase-associated lipocalin to predict PN

161 nding protein, redox-active iron, IL-18, and neutrophil gelatinase-associated lipocalin to predict vi

162 on of apoptotic pathways, and no increase in neutrophil gelatinase-associated lipocalin to suggest tu

163 Renal vein neutrophil gelatinase-associated lipocalin, tumor necros

164 observed glycoproteins (e.g., cadherin 5 and neutrophil gelatinase-associated lipocalin) typically ci

165 We aimed to determine whether urinary neutrophil gelatinase-associated lipocalin (uNGAL) can a

166 Urinary neutrophil gelatinase-associated lipocalin (uNGAL) could

167 tudies evaluating the cut-off level of urine neutrophil gelatinase-associated lipocalin (uNGAL) for d

168 Urinary neutrophil gelatinase-associated lipocalin (uNGAL) has b

169 Urine neutrophil gelatinase-associated lipocalin (uNGAL) has s

170 reatinine ratio (uDKK3/uCr), urine and serum neutrophil gelatinase-associated lipocalin (uNGAL, sNGAL

171 ysC]) with a tubular damage biomarker (urine neutrophil gelatinase-associated lipocalin [uNGAL]), for

172 L versus 97.8 +/- 10.1 mg/dL, P < 0.05), and neutrophil gelatinase-associated lipocalin urine protein

173 Urinary neutrophil gelatinase-associated lipocalin was measured

174 were elevated in intrinsic AKI, but urinary neutrophil gelatinase-associated lipocalin was most usef

175 Urine neutrophil gelatinase-associated lipocalin was the most

176 KIM-1 [kidney injury molecule-1], and NGAL [neutrophil gelatinase-associated lipocalin]) were evalua

177 e presence of recombinant wild-type sequence neutrophil gelatinase-associated lipocalin, wild-type cy

178 Combining urinary neutrophil gelatinase-associated lipocalin with a novel